Nine-valent vaccine is short for nine-valent cervical cancer vaccine, and according to its insert, its long-term protective effect was not found to be highly intraepithelial neoplasia due to the nine types of HPV viral infections prevented by the nine-valent vaccine in women aged 16-26 years who were followed up for up to 7.6 years and women aged 9-16 years who were followed up for up to 6.4 years. There are individual differences in the length of effectiveness of the nine-valent cervical cancer vaccine. The nine-valent cervical cancer vaccine, which is made from the outer envelope of the human papillomavirus, contains human papillomavirus antigens but has low toxicity, and after entering the human body, it can activate the human body’s immune system to produce the corresponding antibodies, thus playing a role in preventing cervical cancer. Since there are individual differences in the duration of antibodies in the human body, there is no fixed time for the duration of effectiveness of the vaccine after vaccination. According to the instruction manual of HPV vaccine, the study of antibody persistence after HPV vaccination is still continuing, and the phase study has been completed, and the follow-up study still needs to be continued. HPV vaccine is not a substitute for HPV screening, and regular medical checkups should be conducted after cervical cancer vaccination so that abnormalities can be detected and treated in a timely manner in order to avoid delays that could lead to adverse consequences.